Trials / Completed
CompletedNCT04241367
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 420 (actual)
- Sponsor
- National Cancer Center, Korea · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Detailed description
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. * Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples. * Correlation analysis of KRAS mutation results with clinical data. Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. * Gene panel composition for pancreatic cancer therapeutic target determination and monitoring. * A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients. * Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
Conditions
Timeline
- Start date
- 2019-03-28
- Primary completion
- 2021-06-03
- Completion
- 2025-12-31
- First posted
- 2020-01-27
- Last updated
- 2026-04-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04241367. Inclusion in this directory is not an endorsement.